Literature DB >> 18988696

Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Haitian Lu1, Barbara L F Kaplan, Thitirat Ngaotepprutaram, Norbert E Kaminski.   

Abstract

Inducible costimulator (ICOS), a prototypic T cell costimulator, is induced on activated T cells. ICOS regulates T cell activation and Th cell differentiation and is principally involved in humoral immune responses. Previous work showed that T cell accessory function is modulated by the plant-derived cannabinoid, delta-9-tetrahydrocannabinol (Delta(9)-THC). In light of an emerging role by ICOS in T cell-mediated immunity, the objective of this study was to investigate the effect of Delta(9)-THC on ICOS in activated mouse T cells. Induction of ICOS mRNA levels by phorbol ester (PMA) plus ionomycin (Io) activation in mouse splenocytes was attenuated by Delta(9)-THC in a concentration-related manner. Similar results were obtained in the mouse T cell line, EL4.IL-2. Anti-CD3/CD28 induced ICOS expression on CD4(+) splenic T cells, which was suppressed by Delta(9)-THC in a time- and concentration-related manner. The PMA/Io-induced icos promoter luciferase reporter activity was also down-regulated by Delta(9)-THC, suggesting that the suppression of ICOS expression by Delta(9)-THC occurs at the transcriptional level. Moreover, transcriptional activation of the NFAT was also down-regulated by Delta(9)-THC as shown by a NFAT luciferase reporter assay, which is consistent with a putative role of NFAT in regulating ICOS expression. Collectively, Delta(9)-THC suppresses ICOS expression in activated T cells, and this suppression may be related, in part, to its modulation of NFAT signaling. The emerging role of ICOS in a wide range of immune-related diseases also suggests that it may represent a potential therapeutic target, which could be modulated by cannabinoid compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18988696      PMCID: PMC2631366          DOI: 10.1189/jlb.0608390

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  41 in total

1.  The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.

Authors:  A J Coyle; S Lehar; C Lloyd; J Tian; T Delaney; S Manning; T Nguyen; T Burwell; H Schneider; J A Gonzalo; M Gosselin; L R Owen; C E Rudd; J C Gutierrez-Ramos
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

2.  ICOS is essential for effective T-helper-cell responses.

Authors:  A Tafuri; A Shahinian; F Bladt; S K Yoshinaga; M Jordana; A Wakeham; L M Boucher; D Bouchard; V S Chan; G Duncan; B Odermatt; A Ho; A Itie; T Horan; J S Whoriskey; T Pawson; J M Penninger; P S Ohashi; T W Mak
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

3.  ICOS is critical for CD40-mediated antibody class switching.

Authors:  A J McAdam; R J Greenwald; M A Levin; T Chernova; N Malenkovich; V Ling; G J Freeman; A H Sharpe
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

4.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

5.  Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.

Authors:  X Li; N E Kaminski; L J Fischer
Journal:  Int Immunopharmacol       Date:  2001-04       Impact factor: 4.932

6.  Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes.

Authors:  A C Herring; N E Kaminski
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

7.  AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun.

Authors:  B L Faubert; N E Kaminski
Journal:  J Leukoc Biol       Date:  2000-02       Impact factor: 4.962

8.  Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.

Authors:  A J McAdam; T T Chang; A E Lumelsky; E A Greenfield; V A Boussiotis; J S Duke-Cohan; T Chernova; N Malenkovich; C Jabs; V K Kuchroo; V Ling; M Collins; A H Sharpe; G J Freeman
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

9.  Induction, binding specificity and function of human ICOS.

Authors:  K C Beier; A Hutloff; A M Dittrich; C Heuck; A Rauch; K Büchner; B Ludewig; H D Ochs; H W Mages; R A Kroczek
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

10.  Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes.

Authors:  Marisela Agudelo; Cathy Newton; Ray Widen; Tracy Sherwood; Liang Nong; Herman Friedman; Thomas W Klein
Journal:  J Neuroimmune Pharmacol       Date:  2007-09-27       Impact factor: 4.147

View more
  11 in total

1.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

Review 2.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

3.  Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

Authors:  Jessica M Sido; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

4.  Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120.

Authors:  Weimin Chen; Barbara L F Kaplan; Schuyler T Pike; Lauren A Topper; Nicholas R Lichorobiec; Steven O Simmons; Ram Ramabhadran; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2012-08-16       Impact factor: 4.962

5.  Induction of the aryl hydrocarbon receptor-responsive genes and modulation of the immunoglobulin M response by 2,3,7,8-tetrachlorodibenzo-p-dioxin in primary human B cells.

Authors:  Haitian Lu; Robert B Crawford; Jose E Suarez-Martinez; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2010-08-11       Impact factor: 4.849

6.  A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10.

Authors:  Rebecca H Robinson; Joseph J Meissler; Xiaoxuan Fan; Daohai Yu; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-16       Impact factor: 4.147

7.  Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin.

Authors:  Qiang Zhang; Sudin Bhattacharya; Douglas E Kline; Robert B Crawford; Rory B Conolly; Russell S Thomas; Norbert E Kaminski; Melvin E Andersen
Journal:  BMC Syst Biol       Date:  2010-04-01

8.  Establishment of an immunoglobulin m antibody-forming cell response model for characterizing immunotoxicity in primary human B cells.

Authors:  Haitian Lu; Robert B Crawford; Colin M North; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2009-09-18       Impact factor: 4.849

9.  Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.

Authors:  Tyrell Simkins; Robert B Crawford; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-29       Impact factor: 4.147

10.  Aqueous extracts from dietary supplements influence the production of inflammatory cytokines in immortalized and primary T lymphocytes.

Authors:  Paul R Hanlon; Melissa G Robbins; Chris Scholl; David M Barnes
Journal:  BMC Complement Altern Med       Date:  2009-12-14       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.